Overview

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure common medical outcomes for this type of patient such as bleeding and stroke.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Research & Development, LLC

Treatments:

Rivaroxaban
Vitamin K
Vitamins